# Research on *Mycobacterium avium* during the period 1995 to 2009

M. Kaevska, K. Hruska

Veterinary Research Institute, Brno, Czech Republic

**ABSTRACT**: Papers on *Mycobacterium avium*, published between 1995 and 2009 that are indexed in the databases Web of Science<sup>®</sup> (Thomson Reuters) and PubMed (U.S. National Library of Medicine) were analysed and 3377 papers, published by 11 197 authors from 2630 institution and 75 countries were compared. *Mycobacterium avium* is represented by four subspecies (*M. avium* subsp. *avium*, *M. avium* subsp. *silvaticum*, *M. avium* subsp. *silvaticum*, *M. avium* subsp. *hominissuis*, and *M. avium* subsp. *paratuberculosis*). Mycobacteria play an important role as human and animal pathogens and represent a potential risk to consumers as food and environmental pathogens and immunomodulators.

Keywords: publications; analysis; health risk; food safety

The importance of mycobacteria and their impact on human health has been widely acknowledged in the literature, and the number of publications dedicated to this problem is steadily increasing. Mycobacterial species not belonging to the Mycobacterium tuberculosis complex are known as environmental or potentially pathogenic mycobacteria. Of these, the Mycobacterium avium complex has been studied the most. The taxonomy of Mycobacterium avium, originally established on the basis of serological characteristics and virulence, has changed under the influence of more sophisticated identification methods. At present, the terminology is not clear and not used uniformly. The term 'Mycobacterium avium complex' was originally used to define a group of closely related organisms that can be divided into two separate species, Mycobacterium avium and M. intracellulare, consisting of 28 serovars. With the development of molecular biology, the species M. avium has been described in more detail. Mycobacterium avium is comprised of four subspecies, which are known animal pathogens; however they differ in

their phenotypic characteristics and host susceptibility. Mycobacterium avium subsp. avium (MAA) is primarily a bird pathogen, causing tuberculous lesions in many different organs and most commonly systemic disease. It affects mainly domestic fowl, although it has been described in a wide variety of domestic and wild bird species (Thorel et al., 1997). Mycobacterium avium subsp. silvaticum has been described as a causative agent of tuberculosis in wood pigeons (Thorel et al., 1990). It differs from MAA in its dependence on mycobactin for primary culture. Mycobacterium avium subsp. hominissuis causes mycobacteriosis in pigs and other animals, as well as humans (Mijs et al., 2002). Mycobacterium avium subsp. paratuberculosis (MAP) is the etiological agent of paratuberculosis, a chronic enteric disease in cattle and wild ruminants. Of all the *M. avium* subspecies, MAP has the greatest importance, causing economic losses (Kennedy and Benedictus, 2001; Hasonova and Pavlik, 2006; Groenendaal and Wolf, 2008; Kudahl et al., 2008; Pillars et al., 2009). Its connection to Crohn's disease has been debated for the last two decades (Bull

Supported by the Ministry of Agriculture of the Czech Republic (Grant No. MZE 0002716202) and the Ministry of Education, Youth and Sports of the Czech Republic (AdmireVet; No. CZ.1.05/2.1.00/01.0006-ED 0006/01/01).

et al., 2003; Scanu et al., 2007). Papers dealing with MAP or paratuberculosis have been excluded from the search results, because an analytical review paper on paratuberculosis has been published only recently (Kaevska and Hruska, 2010).

One of the main aspects of research on *Mycobacterium avium* species is their clinical relevance. There is evidence to indicate that the incidence of human disease has been steadily increasing (Griffith et al., 2007). This is probably due to the influence of many factors; for example, an increase in the frequency of diseases suppressing the immune system which in turn increases susceptibility to mycobacterial infection. An increasingly aging population in developed countries, as well as an increased presence of mycobacteria in the human environment or the development of resistance to the most commonly used desinfectants, can all play a role. *M. avium* is often described as the causal agent of pulmonary infections in eld-

Table 1. Selected books and e-articles (download the full paper PDF from http://vetmed.vri.cz to use the hyperlinks)

#### BOOKS

#### The Ecology of Mycobacteria: Impact on Animal's and Human's Health (Kazda et al., 2009)

http://www.springer.com/public+health/book/978-1-4020-9412-5

http://centaur.vri.cz/news/prilohy/pril1219.pdf

http://www.amazon.com/Ecology-Mycobacteria-Impact-Animals-Humans/dp/1402094124/ref=sr\_1\_39?s=STO RE&ie=UTF8&qid=1285834438&sr=1-39

#### Molecular Mycobacteriology: Techniques and Clinical Applications

http://www.amazon.com/Molecular-Mycobacteriology-Techniques-Clinical-Applications/dp/0824702409/ref= sr\_1\_20?s=STORE&ie=UTF8&qid=1285833809&sr=1-20

#### Improved Mycobacterium avium Complex Detection Methods (AwwaRF Report)

http://www.amazon.com/Improved-Mycobacterium-Complex-Detection-Methods/dp/1843396270/ref=sr\_1\_3? s=books&ie=UTF8&qid=1285833426&sr=1-3

#### Pathogenic Mycobacteria in Water: A Guide to Public Health Consequences, Monitoring and Management

http://www.amazon.com/Pathogenic-Mycobacteria-Water-Consequences-Monitoring/dp/9241562595/ref=sr\_1 \_32?s=STORE&ie=UTF8&qid=1285834313&sr=1-32

#### Tuberculosis and Nontuberculosis Mycobacterial Infections

http://www.amazon.com/Tuberculosis-Nontuberculosis-Mycobacterial-Infections-Schlossberg/dp/0071439137/ref=sr\_1\_33?s=STORE&ie=UTF8&qid=1285834438&sr=1-33

#### Mycobacterium avium Complex

http://www.amazon.com/Mycobacterium-Avium-Complex-Frederic-Miller/dp/6131697841/ref=sr\_1\_9?s=book s&ie=UTF8&qid=1285833426&sr=1-9

## Nontuberculous Mycobacteria: Nontuberculous Mycobacteria, Mycobacterium Avium Complex, Mycobacterium Kansasii, Mycobacterium Cosmeticum

http://www.amazon.com/Nontuberculous-Mycobacteria-Mycobacterium-Kansasii-Cosmeticum/dp/1155677714/ref=sr\_1\_18?s=STORE&ie=UTF8&qid=1285833809&sr=1-18

#### **E-ARTICLES**

#### M. avium – intracellulare (2010-01-12)

http://emedicine.medscape.com/article/222664-overview

#### M. avium complex

http://www.wrongdiagnosis.com/m/mycobacterium\_avium\_complex/intro.htm

### Sources of Infection: Mycobacterium Avium Infections in Pigs, Humans and Birds in Norway (Science Daily 2010-

02-14)

http://www.sciencedaily.com/releases/2010/02/100203091600.htm

#### You Can Prevent MAC (Disseminated Mycobacterium Avium Complex Disease)

http://www.cdc.gov/hiv/resources/brochures/mac.htm

Amoeba symbiosis	Schmitz-Esser et al., 2010
Mycobacterial glycopeptidolipids in pathogenesis	Schorey and Sweet, 2008
Genetic background of virulence	Jang et al., 2008
Contamination of mammalian cell culture	Lelong-Rebel et al., 2009
	Skoric et al., 2007
	Griffith, 2007
	Griffith et al., 2007
Atypical mycobacteriosis, diagnosis and treatment	Kasperbauer and Daley, 2008
	Sexton and Harrison, 2008
	Fuschillo et al., 2008
	Esteban and Ortiz-Perez, 2009
	Wachtman and Mansfield, 2008
	Bonham et al., 2008
HIV and immunodeficiency	Corti and Palmero, 2008
	Herzmann and Lange, 2010
	Pietras et al., 2010
Mycobacteriosis in transplant recipients	Daley, 2009
Complications of infliximab therapy	Salvana et al., 2007

Table 2. Selected review articles

erly or immunosuppressed patients (Falkinham, 1996). Environmental sources, namely potable water, showers or swimming pools are the main sources of infection, as human to human transmission has not been recorded (Falkinham, 1996; Primm et al., 2004; van Ingen et al., 2009). A recently published book has summarised the impact of mycobacteria in the environment on human and animal health (Kazda et al., 2009). Their ubiquitous nature and unique physiological characteristics enable them to survive and persist in natural as well as manmade environments thus providing a constant source of contact with humans and animals. Many publications dealing with different aspects of Mycobacterium avium complex interaction with humans or animals have been published (Table 1 and Table 2).

The Web of Knowledge<sup>®</sup> portal (Thomson Reuters) is a unique tool that can be used to analyse literature from a very representative pool of scientific journals. Previous analyses of publications pertaining to paratuberculosis (Hruska, 2004; Kaevska and Hruska, 2010) have demonstrated its usefulness. The aim of this analysis is concerned with the number of publications on *Mycobacterium avium* (excluding paratuberculosis) and to assess the trend in research for the past 15 years, during which time the number of papers on MAP and paratuberculosis has evidently increased.

#### MATERIAL AND METHODS

Web of Science, Science Citations Index Expanded, Social Sciences Citation Index and Art and Humanities Index databases<sup>®</sup> (Thomson Reuters) were used to search for articles published between 1995 and 2009 and separately, 1995 to 1999, 2000 to 2004 and 2005 to 2009 using the search profile [("*Mycobacterium avium*" OR "M. avium" NOT (paratuberculosis OR Johne's OR Johnes")]. Search results were refined using the following key words: water, soil, (manure OR faeces OR feces OR slurry), milk, meat and environment.

	1995–1999	2000-2004	2005-2009	1995-2009
Web of Science				
All publications	1497	1003	877	3377
Authors	5173	3757	3779	11 197
Institutions	1263	1101	1129	2630
Countries	59	60	53	75
Water	46	71	89	206
Soil	11	14	18	43
Manure OR faeces OR feces OR slurry	6	2	6	14
Milk	3	0	0	3
Meat	2	2	5	9
Environment	33	35	44	112
PubMed				
All publications	1784	1173	1012	3965
Limit				
Human	1415	856	754	3022
Animal	342	284	220	845
Water	36	58	71	165
Soil	13	14	13	40
Manure OR faeces OR feces OR slurry	20	6	7	33
Milk	4	2	2	8
Meat	7	5	6	18
Environment	58	56	63	177

Table 3. Search results using the profile ("Mycobacterium avium" OR "M. avium") NOT (paratuberculosis OR Johne's OR Johnes)

The Web of Science database has unique tools that enable different analyses to be performed on the search results. These were used to analyse the authors, institutions, countries and funding agencies which have the highest number of research papers in this field over the last five years. The following parameters were applied and the results are presented:

- Summary of the number of papers published, using "*Mycobacterium avium*" and related keywords as the topic in PubMed and WOS databases.
- Authors who published ten or more papers on the topic in the last five years, compared to their publication activity in the two previous five year periods.

- Institutions that published ten or more papers on the topic in the last five years, compared to their publication activity in the two previous five year periods.
- Countries that published twenty or more papers on the topic in the last five years, compared to their publication activity in the two previous five year periods.
- The top 20 most frequently cited papers on the topic in the last 15 years.

The database PubMed<sup>©</sup> (U.S. National Library of Medicine) was searched for papers, published in the same time span using the same search profiles and limits. The searches from PubMed were also limited to humans and to animals.

	Authors	2005-2009	2000-2004	1995–1999
1	Koh WJ	25	2	
2	Kwon OJ	23	2	
3	Yano I	18	3	3
4-5	Appelberg R	16	20	18
4-5	Bermudez LE	16	31	37
6	Pavlik I	14	8	2
7	Lee KS	13	2	1
8	Naka T	11	1	
9	Matlova L	10	4	

Table 4. Authors publishing ten or more papers in the period from 2005 to 2009, in comparison to their publication activity in the previous five year periods

#### **RESULTS AND DISCUSSION**

A summary of the number of papers published using the search profile [("Mycobacterium avium" OR "M. avium") NOT (paratuberculosis OR Johne's OR Johnes)] in PubMed and WOS databases is presented in Table 3. The total number of publications has decreased during the five years periods investigated (from 1995 to 2009). There are differences in the absolute numbers between the databases due to their differing journal coverage, but the general trends are evident in both databases.

Tables 4 to 7 display the search result analyses performed using the Web of Science utilities. Table 4 presents authors that published ten or more papers in the last five years. It reveals that all the authors were active in the field for at least ten years,

Table 5. Institutions with 10 or more publications in the field between 2005 and 2009, in comparison to their publication activity in the previous five-year periods

	Institutions		2005-2009	2000-2004	1995–1999
1	Sungkyunkwan University		24	2	
2	Harvard University		18	49	41
3	Oregon State University		16	10	
4	University of Porto		15	21	26
5-6	National Institute for Allergy and Infectious Diseases		14	24	30
5-6	Veterinary Research Institute, Brno	▲	14	8	2
7	Duke University		13	12	16
8	University of Notre Dame		11	9	
9–11	Boston University		10	17	24
9–11	Johns Hopkins University		10	21	34
9–11	University of Texas		10	25	66

 $\blacktriangle$  = increase, compared to 2000 to 2004

	Country		2005-2009	2000-2004	1995–1999
1	USA	▼	344	499	834
2	Japan		92	94	69
3	Germany	▼	50	62	73
4	France	▼	49	56	138
5	Spain		42	39	37
6	England	▼	39	67	95
7	South Korea	▲	36	6	5
8	Italy	▼	32	46	61
9–10	Canada		31	29	50
9–10	India	<b></b>	31	14	6
11–12	Brazil	<b></b>	27	23	11
11–12	Portugal		27	27	27
13	Czech Republic	<b></b>	25	22	10
14–15	Australia	▼	21	43	42
14-15	Netherlands	<b></b>	21	12	17

Table 6. Countries with 20 or more publications during 2005–2009, in comparison to the previous five-year periods

▼ = greater than 10% decrease, compared to 2000 to 2004

 $\blacktriangle$  = increase, compared to 2000 to 2004

five of them for 15 years. It is evident that institutions producing ten or more papers published between 2005 and 2009, must have all been working on MAA for at least ten years, with eight of them for 15 years (Table 5). The declining number of publications on the topic shown in Table 5 (with the exception of Sungkyunkwan University, Oregon State University, the Veterinary Research Institute, Brno and the University of Notre Dame) is in agreement with the general trend shown in Table 3. Interest in research on MAA is evident in 15 countries from five continents with 21 or more papers published in the last five years (Table 6). The decline in the number of papers published by authors from the USA, Germany, France, England, Italy, and Australia in 2005 to 2009 exceeds 10% when compared to the previous five year period. In contrast, authors from South Korea, India, Brazil, the Czech Republic and the Netherland published more papers in the most recent period than in the one previous to it.

Table 7 is a list of the most frequently cited papers. It is obvious that the most frequently cited paper by Palella et al. (1998) does not owe its 4425 citations to work on MAA but rather its link to HIV. However, papers dealing with the epidemiology of nontuberculous mycobacteria by Falkinham (1996), cited 414 times and by Griffith et al. (2007), cited 320 times reflect actual contributions to studies on *M. avium*.

Overall, the number of publications on *M. avium* is not increasing, contrary to those dealing with *Mycobacterium avium* subsp. *paratuberculosis* (Kaevska and Hruska, 2010). Nevertheless, the interest in MAA remains high, due to the series of opportunistic infections it can cause in immunocompromised humans. Moreover, pathological lesions in pigs caused by non-tuberculous mycobacteria can result in great economical losses and pose a risk to some consumers (Shitaye et al., 2006). Apart from the impact of MAA on human and animal health, this species is also the subject of interest for ecologists, investigating its persistence in the environment.

4435	Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection New England Journal of Medicine 338, 853–860
641	Collins LA, Franzblau SG (1997) Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Myco- bacterium avium Antimicrobial Agents and Chemotherapy 41, 1004–1009
527	Lien E, Sellati TJ, Yoshimura A, Flo TH, Rawadi G, Finberg RW, Carroll JD, Espevik T, Ingalls RR, Radolf JD, Golenbock DT (1999) <b>Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products</b> Journal of Biological Chemistry 274, 33419–33425
451	Means TK, Wang SY, Lien E, Yoshimura A, Golenbock DT, Fenton MJ (1999) <b>Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis</b> Journal of Immunology 163, 3920–3927
448	Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, Relier LB (1997) The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults Clinical Infectious Diseases 24, 584–602
441	Hogg RS, Heath KV, Yip B, Craib KJP, O'Shaughnessy MV, Schechter MT, Montaner JSG (1998) <b>Improved survival among HIV-infected individuals following initiation of antiretroviral therapy</b> Journal of the American Medical Association 279, 450–454
414	Falkinham JO (1996) Epidemiology of infection by nontuberculous mycobacteria Clinical Microbiology Reviews 9, 177–215
322	Orenstein JM, Fox C, Wahl SM (1997) Macrophages as a source of HIV during opportunistic infections Science 276, 1857–1861
320	Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K (2007) <b>An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases</b> American Journal of Respiratory and Critical Care Medicine 175, 367–416
314	Boons GJ (1996) <b>Strategies in oligosaccharide synthesis</b> Tetrahedron 52, 1095–1121

DIRECTION DEPARTOR OF INCOMENCES AND ADDRESS TO A STORAGE TO A STORAGE TO A STORAGE AN ANO. COMPANIATION ADDRESS ADDRES	Immune reconstitution inflammatory syndrome – Emergence of a unique syndrome during highly active antiretroviral therapy Medicine 81, 213–227 206 Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA (2001) Differential regulation of nitric oxide synthase-2 and arginase-1 by type 2 cytokines in vivo: Granulomatous pathology is shaped by the pattern o	210 Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002) Immune reconstitution inflammatory syndrome – Emergence of a unique syndrome during highly active antiretroviral therapy Medicine 81, 213–227
<ul> <li>Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)</li> <li>Immune reconstitution inflammatory syndrome – Emergence of a unique syndrome during highly active antiretroviral therapy</li> <li>Medicine 81, 213–227</li> <li>Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA (2001)</li> <li>Differential reconstruction of ritric oxide expenses 2 and arcinese. J hy true 1 (hyne 2 cytokines in vivor Granulometrous mathematics haved by the national control of ritric oxide expenses. 2 and arcinese. J hy true 1 (hyne 2 cytokines in vivor Granulometrous mathematics covide expenses. 2 and arcinese. J hy true 1 (hyne 2 cytokines in vivor Granulometrous mathematics)</li> </ul>	210 Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)	
<ul> <li>DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> <li>Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)</li> <li>Immune reconstitution inflammatory syndrome – Emergence of a unique syndrome during highly active antiretroviral therapy</li> <li>Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA (2001)</li> <li>Differential reconstitution of intrivious contrase. 2 and arrinase. 1 by true 2, cynolines in vivo. Granulomators use holdow is should by the vation of the set of a true of a true of a true of a vivo. Granulomators and arrives and arrivables of a vivo. Granulomators use holdow is should by the vation of the set of a vivo. Granulomators used by the vation of the set of a vivo. Granulomators and by the vation of the set of a vivo. Granulomators and by the vation of the set of a vivo. Granulomators used by the vation of the vation of a vivo. Granulomators and by the vation of the value of a vivo. Granulomators and by the value of the value of a vivo. Granulomators with low of viter over the value of the value of the value of viter over the value of a vivo. Granulomators and by the value of the value of value of a vivo. Granulomators and by the value of value o</li></ul>	<ul> <li>DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> <li>Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)</li> </ul>	210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000) Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy Annals of Internal Medicine 133, 447–454
<ul> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Protease inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations</li> <li>Clinical Pharmacokinetics 32, 194–209</li> <li>DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> <li>Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegar wala F, Trautner BW (2002)</li> <li>Immune reconstitution inflammatory syndrome – Emergence of a unique syndrome during highly active antiretroviral therapy</li> <li>Medicine 81, 213–227</li> <li>Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA (2001)</li> <li>Differential reconflation of intric oxide southese 2 and arcinese 1 hy true 2 cutokines in vitor Granulometory scholaer is chansed by the partient of the partient of the partient of a partienee of a unique syndrome during highly active antiretroviral therapy</li> </ul>	<ul> <li>210 Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li><b>Protease inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations</b></li> <li>Clinical Pharmacokinetics 32, 194–209</li> <li>210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> <li>210 Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)</li> </ul>	<ul> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Protease inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations</li> <li>Clinical Pharmacokinetics 32, 194–209</li> <li>DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> </ul>
<ul> <li>214 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease New England Journal of Medicine 344, 824–831</li> <li>210 Barry M, Gibbons S, Back D, Mulcahy F (1997) Protease inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations Clinical Pharmacokinetics 32, 194–209</li> <li>210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000) Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy Annals of Internal Medicine 133, 447–454</li> <li>210 Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegar wala F, Trautner BW (2002) Immune reconstitution inflammatory syndrome - Emergence of a unique syndrome during highly active antiretroviral therapy Medicine 81, 213–227</li> <li>206 Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA (2001) Diffeomolic Inconduction of third covido combased. The travel <i>J travel J travel C</i>, Wynn TA (2001)</li> </ul>	<ul> <li>214 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>7 The cost effectiveness of combination antiretroviral therapy for HIV disease</li> <li>10 New England Journal of Medicine 344, 824–831</li> <li>210 Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>210 Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations</li> <li>210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>210 Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>210 Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)</li> </ul>	<ul> <li>214 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li><b>The cost effectiveness of combination antiretroviral therapy for HIV disease</b></li> <li>New England Journal of Medicine 344, 824–831</li> <li>210 Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li><b>Protease inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations</b></li> <li>210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> </ul>
<ul> <li>Erench MA, Frice P, Stone SF (2004)</li> <li>Immune restoration disease after antiretroviral therapy Aids 18, 1615–1627</li> <li>214 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectiveness of combination antiretroviral therapy for HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>210 Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Paterase inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations</li> <li>210 Destinone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy Annals of Internal Medicine 133, 447–454</li> <li>210 Destinone SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarvala F, Trautner BW (2002)</li> <li>Innuune reconstitution inflammatory syndrome - Emergence of a unique syndrome during highly active antiretroviral therapy Medicine 81, 213–227</li> <li>216 Hesse M, Modelell M, Flamme AC, Schito M, Flentes JM, Cheever AW, Pearce EJ, Wym TA (2001)</li> </ul>	<ul> <li>French MA, Price P, Stone SF (2004)</li> <li>Immune restoration disease after antiretroviral therapy</li> <li>Aids 18, 1615–1627</li> <li>Ereedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectiveness of combination antiretroviral therapy for HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Protease inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations</li> <li>Clinical Pharmacokinetics 32, 194–209</li> <li>DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> <li>Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)</li> </ul>	<ul> <li>216 French MA, Price P, Stone SF (2004)</li> <li>Immune restoration disease after antiretroviral therapy</li> <li>Aids 18, 1615–1627</li> <li>214 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectiveness of combination antiretroviral therapy for HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>210 Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Protease inhibitors in patients with HIV disease – Clinically important pharmacokinetic considerations</li> <li>210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy</li> <li>Annals of Internal Medicine 133, 447–454</li> </ul>
<ul> <li>Eidock DA, Wellems TE (1997)</li> <li>Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of program</li> <li>Proceedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>French MA, Price P, Stone SF (2004)</li> <li>Erench MA, Price P, Stone SF (2004)</li> <li>Immune restoration disease after antiretroviral therapy</li> <li>Aids 18, 1615–1627</li> <li>States of Combination antiretroviral therapy in HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Directase inhibitors in patients with HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>Storease inhibitors in patients with HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Destrome IA, Pomenant RM, Picese – Clinically important pharmacokinetic considerations</li> <li>Clinical Pharmacokinetics 32, 194–209</li> <li>Distinone IA, Pomenant RM, Babinchak TJ (2000)</li> <li>Informatory rections in HIV-1-infected persons after initiation of highly active antirectoviral therapy Anals of Internal Medicine 133, 447–454</li> <li>Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg BS, Atmar RJ, Musher DM, Gathe JC, Visnegarvala F, Trautner BW (2002)</li> <li>Innumue reconstitution inflammatory syndrome – Emergence of a unique syndrome during highly active antirectoviral therapy Medicine 83, 213–227</li> <li>Hese M, Modoli M, Fientes JM, Cheever AW, Perce EJ, Wynn TA (2001)</li> <li>Hese M, Modoli M, Fientes JM, Cheever AW, Perce EJ, Wynn TA (2001)</li> </ul>	<ul> <li>Eidock DA, Wellems TE (1997)</li> <li>Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WB99210 but does not affect the intrinsic activity of programation with human dihydrofolate reductase renders malaria parasites insensitive to WB99210 but does not affect the intrinsic activity of program proceedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>French MA, Price P, Stone SF (2004)</li> <li>French MA, Price P, Stone SF (2004)</li> <li>Immue restoration disease after antiretroviral therapy Aids 18, 1615–1627</li> <li>Freedberg KA, Losina E, Weinstein MC, Pattel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Freedberg KA, Losina E, Weinstein MC, Pattel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectiveness of combination antiretroviral therapy for HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Darry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Derotease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations</li> <li>Clinical Pharmacokinetics 32, 194–209</li> <li>Desimone IA, Pomenanz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy Annals of Internal Medicine 133, 447–454</li> <li>Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Amar RL, Musher DM, Gathe JC, Visnegar wala F, Trautner BW (2002)</li> </ul>	<ul> <li>216 Fidock DA, Wellems TE (1997)</li> <li>Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of programil</li> <li>Proceedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>216 French MA, Price P, Stone SF (2004)</li> <li>Immune restoration disease after antiretroviral therapy</li> <li>214 Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The complexity of provident of the antiretroviral therapy for HIV disease</li> <li>210 Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Protease inhibitors in patients with HIV disease - Clinically important pharmacokinetic considerations</li> <li>210 DeSimone JA, Pomerantz RJ, Babinchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-inflected persons after initiation of highly active antiretroviral therapy Annals of Internal Medicine 133, 447–454</li> </ul>
<ul> <li>Nicholson S, Bonecinialmeida MDG, Silva JRLE, Nathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996) nutuel of Experimental Medicine 183, 2293–2302</li> <li>Fidock DA, Wellems TE (1997)</li> <li>Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of pro- transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of pro- transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of pro- grand</li> <li>French MA, Price P, Stone SF (2004)</li> <li>French MA, Price P, Stone SF (2004)</li> <li>Treedberg KA, Losina E, Weinstein MC, Patitel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Teredberg KA, Losina E, Weinstein MC, Patitel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Teedberg KA, Losina E, Weinstein M, Huvala H, Patase</li> <li>Shar M (gibone S, Back D, Mulcaly F (1997)</li> <li>Diary M (gibone S, Back D, Mulcaly F (1997)</li> <li>Diary M (gibone S, Back D, Mulcaly F (1997)</li> <li>Diary M (gibone S, 2004)</li> <li>Diary M (gibone S, Back D, Mulcaly F (1997)</li> <li>Diary M (gibone S, Back D, Mulcaly F (1997)</li> <li>Diary M (gibone S, Back D, Mulcaly F (1997)</li> <li>Diary M (gibone S, Jack D, Mulcaly F (1997)</li> <li>Diary M (gibone S, Back D, Mulcaly F (1997)</li> <li>Diary M (gibone S, 194–209</li> <li>Diary M (gibone S, Harn RL, Musher DM, Gathe C, Visnegarvala F, Frautner BW (2002)</li> <li>Diariana IM (addicine 33, 47–434</li> <li>Shelure SA, Hamill R, Rodriguez Barrada SM, Greenberg SB, Atura RL, Musher DM, Gathe JC, Visnegarvala F, Frautner BW (2002)</li> <li>Dimmus reconstitution inflammatory syndrome - Emergence of a unique syndrome furtion for theory in cheropy Medicine B1, 213–227</li> <li>Diefenenk SH, Annal RM, C</li></ul>	<ul> <li>Nicholson S, Bonecinialmeida MDG, Silva JRLE, Nathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996)</li> <li>Inducible nitric oxide synthase in pulmonary alreolar macrophages from patients with tuberculosis</li> <li>Pidock DA, Wellems TE (1997)</li> <li>Fidock DA, Wellems TE (1997)</li> <li>Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of progual</li> <li>Proceedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>Erench MA, Price P, Stone SF (2004)</li> <li>Immune restoration disease after antiretroviral therapy</li> <li>Internet St. Jolis E, Weinstein MC, Patiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Teedberg KA, Losina E, Weinstein MC, Patiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectiveness of combination antiretroviral therapy for HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>Barry M, Gibbons S, Back D, Mukahy F (1997)</li> <li>Barry M, Gibbons S, Back D, Mukahy F (1997)</li> <li>Dasmy M, Gibbons S, Back D, Mukahy F (1997)</li> <li>Destinon IA, Pontenzi RJ, Babicchak TJ (2000)</li> <li>Internation in Altoriors in patients with HIV disease - Clinically important pharmacokinetic considerations</li> <li>Clinical Pharmacokinetics 232, 194–209</li> <li>Destinon IA, Ponternaz RJ, Babicchak TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy Annals of Internal Medicine 133, 447–454</li> <li>Shelburne SA, Hannill RJ, Rodriguez-Barradas MC, Greenberg B, Atmar RL, Musher DM, Gathe JC, Visnegarwala F, Trautner BW (2002)</li> </ul>	<ul> <li>Nicholson S, Bonecinialmeida MDG, Silva JRLE, Nathan C, Xie QW, Mumford R, Weidher JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996 Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis Journal of Experimental Medicine 183, 2293–2302</li> <li>Fidock DA, Wellems TE (1997)</li> <li>Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of programiling of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>French MA, Price P, Stone SF (2004)</li> <li>Immune restoration disease after antiretroviral therapy Adds 18, 1615–1627</li> <li>Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectiveness of combination antiretroviral therapy for HIV disease</li> <li>New England Journal of Medicine 344, 824–831</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Barry M, Gibbons S, Back D, Mulcahy F (1997)</li> <li>Destrone A, Pomeranz RJ, Babincha K TJ (2000)</li> <li>Inical Pharmacokinetics 32, 149–209</li> <li>Destinoe JA, Pomeranz RJ, Babincha K TJ (2000)</li> <li>Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy Annals of Internal Medicine 133, 447–454</li> </ul>
<ul> <li>Mocret A, Katham C, Johnson AM, Pradier C, Antunes F, Mukchy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000)</li> <li>Intere 556, 591–596</li> <li>Nicholson S, Bonecinalmeida MDG, Silva JRLF, Mathan C, Xie QW, Munford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996)</li> <li>Intere 556, 591–596</li> <li>Nicholson S, Bonecinalmeida MDG, Silva JRLF, Mathan C, Xie QW, Munford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996)</li> <li>Fidock DA, Wellems TE (1997)</li> <li>Fidock DA, Wellems TE (1997)</li> <li>Finatformation with human dihydrofolate reductase renders malaria parasites insensitive to WR9210 but does not affect the intrinsic activity of program</li> <li>Proceedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>French MA, Price R, Stone SF (2004)</li> <li>French MA, Price R, Stone SF (2004)</li> <li>French MA, Price R, Stone SF (2004)</li> <li>Immer restoritori of disease after antiretroviral therapy (or HIV disease</li> <li>Teredberg KA. Losina E, Weinstein MC. Paltel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Freedberg KA. Losina E, Weinstein MC. Paltel AD. Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Tree dereg KA. Losina E, Weinstein MC. Paltel AD. Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Tree dereg KA. Losina E, Weinstein MC. Paltel AD. Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Tree dereg KA. Losina E, Weinstein MC. Paltel AD. Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Tree dereg KA. Losina E, Weinstein MC. Paleta AD. Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Tree dereg KA. Losina E, Weinstein MC. Paleta AD. Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Tree dere</li></ul>	<ul> <li>Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Landgren JD (2000)</li> <li>ADS across taruops. 1994–98: the EuroSIDA study</li> <li>Ianest 356. 291–296</li> <li>Nicholson S, Bonecinalmeida MDG, Silva JRLF, Nathan C. Xie QW, Munford R, Weidner JR. Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996)</li> <li>Ianto Di Experimental Melcine 183. 2293–2302</li> <li>Fidok DA, Wellems TE (1997)</li> <li>Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of program of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>Fench MA, Pirte P, Stone SF (2004)</li> <li>Teransformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of program for the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>French MA, Pirte P, Stone SF (2004)</li> <li>Treadberg KA, Losina E, Weinstein MC, Patliel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Treedberg KA, Losina E, Weinstein MC, Patliel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectuation disease after antiretroviral therapy for HIV disease</li> <li>The cost effectuation streeroviral therapy for HIV disease</li> <li>The cost effectuates 32, 194–209</li> <li>Barry M, Gibbons S, Back D, Mulcah F (1997)</li> <li>Portease in hibitors in patients with HIV disease</li> <li>Clinical Paramacokinetics 33, 447–454</li> <li>Barry M, Gibbons S, Back D, Mulcah F (1997)</li> <li>Portease in hibitors in patients with HIV disease</li> <li>Clinical Paramacokinetics 33, 447–454</li> <li>Barry M, Gibbons S, Back D, Mulcah F (1997)</li> <li>Portease in hibitors in patients with HIV disease A, Murus RL, Musher DM, Gather C</li></ul>	<ul> <li>Mocroft A, Kaltama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000) <b>AIDS across Europs. 1994–98: the EuroSIDA study</b> Lancet 356, 291–296</li> <li>Nicholson S, Bonecinalmeida MDG, Silva JRLE, Nathan C, Xie QW, Munford R, Weidner JR, Calayeay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996 Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis</li> <li>Nicholson S, Bonecinalmeida MDG, Silva JRLE, Nathan C, Xie QW, Munford R, Weidner JR, Calayeay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996 Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis</li> <li>Edok DA, Wellems TE (1997)</li> <li>Transformation out; human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of programinal proceedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>French MA, Price P, Stone SF (2004)</li> <li>Immure restoration disease after anticetroviral therapy Ads 18, 1615–1627</li> <li>Teredberg KA, Losin E, Weinstein MC, Patiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>Preedberg KA, Losin E, Weinstein MC, Patiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ (2001)</li> <li>The cost effectives of combination anticetroviral therapy for HIV disease</li> <li>New Figland Journal of Medicine 34, 824–831</li> <li>Barry M, Gibbons S, Babic D, Mulcaby F (1997)</li> <li>Preeberg KA, Losin ES, Mulcaby F (1997)</li> <li>Preeberg KA, Losin S, Babichak T (2000)</li> <li>Dinneal O Finema J, Rabinchak T (2000)</li> <li>Informotive reactions in HIV L-infected persons after initiation of highly active antiretroviral therapy Anals of Internal Medicine 133, 447–454</li> </ul>
<ol> <li>Bere EM, Adelon-Mitry J, Kreigel GR, Brahum FT, Reiman KA, Jachu SH, Japour M (1998)</li> <li>Bere EM, Adelon-Mitry J, Kreigel GR, Brahum FT, Reiman KA, Jachu SH, Shou SH, Sho</li></ol>	<ul> <li>267 Race EM, Adelson-Mitry J, Kriegel GR, Barlam TF, Reimann KA, Latvin NL, Japour AJ (1996)</li> <li>Freeding Transpodenterial Jimphadeentis following initiation of proteasa-inhibitor therapy in patients with advanced HIV-1 disease france 531. 352–355</li> <li>239 Mocroft A, Kadama C, Johnson AM, Prader C, Antunes E, Malcahy E, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000)</li> <li>256 Mocroft A, Kadama C, Johnson AM, Prader C, Antunes E, Malcahy E, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000)</li> <li>256 Mocroft A, Statama C, Johnson AM, Prader C, Antunes E, Malcahy E, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000)</li> <li>256 Mocroft A, Kadama C, Johnson AM, Prader C, Antunes E, Malcahy E, Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000)</li> <li>256 Micholson S, Bonccinnalmoid ADG, Silva JRLE, Nathan C, Xie QW, Munford R, Weidner JR, Calaycey J, Geng J, Bocchat N, Linhares C, Ron W, Ho JL (1996)</li> <li>256 Micholson S, Bonccinnalmoid ADG, Silva JRLE, Nathan C, Xie QW, Munford R, Weidner JR, Calaycey J, Geng J, Bocchat N, Linhares C, Ron W, Ho JL (1996)</li> <li>216 Fidock DA, Wellem TE (1997)</li> <li>216 Transformation with human dirydrofolate reductase renders malaria parasites insensitive to W 799210 but does not affect the intrinsic activity of program of the Antional Academy of Sciences of the United States of America 94, 10931–10936</li> <li>216 French MA, Jife J, Stone F (2004)</li> <li>217 Prevedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>218 Previck MA, Jife J, Stone F (2004)</li> <li>219 Prevedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>210 Prevedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>211 Prevedings of the National Academy of Sciences of the United States of America 94, 10931–10936</li> <li>212 Prevedings of the Sational Academy of Sciences of the United States of America 94, 10001</li> <li>213 Preveding R,</li></ul>	<ul> <li>267 Race EM, Adelson-Mitry I, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ (1998)</li> <li>Ford Invicobacterial simpledicatics following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease frame (331, 352–358)</li> <li>259 Mocroft A, Kadama C, Johnson AM, Pradier C, Antunes F. Mulcahy F. Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000)</li> <li>260 Mocroft A, Kadama C, Johnson AM, Pradier C, Antunes F. Mulcahy F. Chiesi A, Phillips AN, Kirk O, Lundgren JD (2000)</li> <li>261 Micholson S, Bonecimalmeida MJOG, Silva RLE, Mathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996)</li> <li>262 Micholson S, Bonecimalmeida MJOG, Silva RLE, Mathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1997)</li> <li>263 Micholson S, Bonecimalmeida MJOG, Silva RLE, Mathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996)</li> <li>264 DA, Weilman TE (1997)</li> <li>205 Ferdok DA, Wellems TE (1997)</li> <li>206 MA, Pricko MA, Prick D, Silva RLE, Mathan C, Xie QW, Aumford R, Weidner JR, Calaycay J, Geng J, Boechat N, Linhares C, Rom W, Ho JL (1996)</li> <li>206 Diarnal of KH Human dihydrofolate reductase readers malaria parasites insensitive to W799210 but does not affect the intrinsic activity of program guant</li> <li>206 MAA, Price J Stone ST (2004)</li> <li>207 Transformation with human dihydrofolate reductase readers malaria parasites insensitive to W799210 but does not affect the intrinsic activity of program testoration sciese activity and sciences of the United States of America 94, 10931–10936</li> <li>208 Transformation with Human dihydrofolate reductase readers malaria parasites insensitive to W799210 but does not affect the intrinsic activity of program for the MA. Price J Stone ST (2004)</li> <li>206 Dammaton With Dr. (2097)</li> <li>207 Teredberg KA, Losina E, Weinten MC, Palei AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, G</li></ul>

#### REFERENCES

- Bonham S, Meya DB, Bohjanen PR, Boulware DR (2008): Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomarkers in Medicine 2, 349–361.
- Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G, Pickup R, Hermon-Taylor J (2003): Detection and verification of Mycobacterium avium subsp paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. Journal of Clinical Microbiology 41, 2915–2923.
- Corti M, Palmero D (2008): Mycobacterium avium complex infection in HIV/AIDS patients. Expert Review of Anti-Infective Therapy 6, 351–363.
- Daley CL (2009): Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Current Opinion in Organ Transplantation 14, 619– 624.
- Esteban J, Ortiz-Perez A (2009): Current treatment of atypical mycobacteriosis. Expert Opinion on Pharma-cotherapy 10, 2787–2799.
- Falkinham JO (1996): Epidemiology of infection by nontuberculous mycobacteria. Clinical Microbiology Reviews 9, 177–215.
- Fuschillo S, De Felice A, Balzano G (2008): Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. European Respiratory Journal 31, 396–406.
- Griffith DE (2007): Therapy of nontuberculous mycobacterial disease. Current Opinion in Infectious Diseases 20, 198–203.
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K (2007): An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American Journal of Respiratory and Critical Care Medicine 175, 367–416.
- Groenendaal H, Wolf CA (2008): Farm-level economic analysis of the US National Johne's Disease Demonstration Herd Project. Javma-Journal of the American Veterinary Medical Association 233, 1852–1858.
- Hasonova L, Pavlik I (2006): Economic impact of paratuberculosis in dairy cattle herds: a review. Veterinarni Medicina 51, 193–211. http://www.vri.cz/docs/ vetmed/51-5-193.pdf
- Herzmann C, Lange C (2010): Infections with non-tuberculous mycobacteria and HIV. Deutsche Medizinische Wochenschrift 135, 1192–1197.

- Hruska K (2004): Research on paratuberculosis: Analysis of publications 1994–2004. Veterinarni Medicina 49, 271–282. http://www.vri.cz/docs/vetmed/49-8-271.pdf
- Jang J, Becq J, Gicquel B, Deschavanne P, NeyrolleS O (2008): Horizontally acquired genomic islands in the tubercle bacilli. Trends in Microbiology 16, 303–308.
- Kaevska M, Hruska K (2010): Analysis of publications on paratuberculosis from 1995 to 2009 with emphasis on the period from 2005 to 2009. Veterinarni Medicina 55, 43–54. http://vri.cz/docs/vetmed/55-02-43. pdf
- Kasperbauer SH, Daley CL (2008): Diagnosis and treatment of infections due to Mycobacterium avium complex. Seminars in Respiratory and Critical Care Medicine 29, 569–576.
- Kazda J, Pavlik I, Falkinham III JO, Hruska K (eds.) (2009): The Ecology of Mycobacteria: Impact on Animal's and Human's Health. 1<sup>st</sup> ed. Springer. XVIII, 522 pp.
- Kennedy DJ, Benedictus G (2001): Control of Mycobacterium avium subsp paratuberculosis infection in agricultural species. Revue Scientifique et Technique de l Office International des Epizooties 20, 151–179.
- Kudahl AB, Nielsen SS, Ostergaard S (2008): Economy, efficacy, and feasibility of a risk-based control program against paratuberculosis. Journal of Dairy Science 91, 4599–4609.
- Lelong-Rebel IH, Piemont Y, Fabre M, Rebel G (2009): Mycobacterium avium-intracellulare contamination of mammalian cell cultures. In Vitro Cellular & Developmental Biology-Animal 45, 75–90.
- Mijs W, de Haas P, Rossau R, Van der Laan T, Rigouts L, Portaels F, van Soolingen D (2002): Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp avium for bird-type isolates and 'M-avium subsp. hominissuis' for the human/porcine type of M-avium. International Journal of Systematic and Evolutionary Microbiology 52, 1505–1518.
- Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998): Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338, 853–860.
- Pietras TA, Baum CL, Swick BL (2010): Coexistent Kaposi sarcoma, cryptococcosis, and Mycobacterium avium intracellulare in a solitary cutaneous nodule in a patient with AIDS: Report of a case and literature review. Journal of the American Academy of Dermatology 62, 676–680.
- Pillars RB, Grooms DL, Wolf CA, Kaneene JB (2009): Economic evaluation of Johne's disease control pro-

grams implemented on six Michigan dairy farms. Preventive Veterinary Medicine 90, 223–232.

- Primm TP, Lucero CA, Falkinham JO (2004): Health impacts of environmental mycobacteria. Clinical Microbiology Reviews 17, 98–106.
- Salvana EMT, Cooper GS, Salata RA (2007): Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients. Journal of Infection 55, 484–487.
- Scanu AM, Bull TJ, Cannas S, Sanderson JD, Sechi LA, Dettori G, Zanetti S, Hermon-Taylor J (2007): Mycobacterium avium subspecies paratuberculosis infection in cases of irritable bowel syndrome and comparison with Crohn's disease and Johne's disease: Common neural and immune pathogenicities. Journal of Clinical Microbiology 45, 3883–3890.
- Schmitz-Esser S, Tischler P, Arnold R, Montanaro J, Wagner M, Rattei T, Horn M (2010): The genome of the amoeba symbiont "candidatus Amoebophilus asiaticus" reveals common mechanisms for host cell interaction among amoeba-associated bacteria. Journal of Bacteriology 192, 1045–1057.
- Schorey JS, Sweet L (2008): The mycobacterial glycopeptidolipids: structure, function, and their role in pathogenesis. Glycobiology 18, 832–841.
- Sexton P, Harrison AC (2008): Susceptibility to nontuberculous mycobacterial lung disease. European Respiratory Journal 31, 1322–1333.
- Shitaye JE, Parmova I, Matlova L, Dvorska L, Horvathova A, Vrbas V, Pavlik I (2006): Mycobacterial and Rhodococcus equi infections in pigs in the Czech Repub-

lic between the years 1996 and 2004: the causal factors and distribution of infections in the tissues. Veterinarni Medicina 51, 497–511. http://www.vri.cz/docs/ vetmed/51-11-497.pdf

- Skoric M, Shitaye EJ, Halouzka R, Fictum P, Trcka I, Heroldova M, Tkadlec E, Pavlik I (2007): Tuberculous and tuberculoid lesions in free living small terrestrial mammals and the risk of infection to humans and animals: a review. Veterinarni Medicina 52, 144–161. http://www.vri.cz/docs/vetmed/52-4-144.pdf
- Thorel MF, Krichevsky M, Levyfrebault VV (1990): Numerical taxonomy of mycobactin-dependent Mycobacteria, emended description of Mycobacterium-avium, and description of Mycobacterium-avium subsp. avium subsp. nov., Mycobacterium-avium subsp. paratuberculosis subsp. nov., and Mycobacterium-avium subsp. silvaticum subsp. nov. International Journal of Systematic Bacteriology 40, 254–260.
- Thorel MF, Huchzermeyer H, Weiss R, Fontaine JJ (1997): Mycobacterium avium infections in animals. Literature review. Veterinary Research 28, 439–447.
- van Ingen J, Boeree MJ, Dekhuijzen PNR, van Soolingen D (2009): Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans. Clinical Microbiology and Infection 15, 888–893.
- Wachtman LM, Mansfield KG (2008): Opportunistic infections in immunologically compromised nonhuman primates. Ilar Journal 49, 191–208.

Received: 2010–09–25 Accepted after corrections: 2010–10–20

Corresponding Author:

Marija Kaevska, Veterinary Research Institute, Hudcova 70, 621 00 Brno, Czech Republic Tel. +420 533 331 618, E-mail: kaevska@vri.cz